论文部分内容阅读
据正在进行的欧洲Ⅱ／Ⅲ期临床试验的3个月的结果表明，Cnrtecs公司的降钙素（calci－tonin）肽口服剂（商品名Macritonin）对骨质疏松症有效。目前市售的降钙素只有鼻内给药和注射制剂。这一研究的结果证实，口服降钙素与鼻内用降钙素有相似的活性，且如对3项标志骨质丢失的尿
Three months of ongoing European Phase II / III clinical trials indicate that Cnrtecs’ calcitonin oral agent (Macritonin) is effective against osteoporosis. Calcitonin is currently marketed only for intranasal administration and injections. The results of this study confirmed that oral calcitonin and intranasal calcitonin have similar activity, and as three markers of bone loss of urine